Stock Update (NASDAQ:RMTI): Rockwell Medical Inc Announces Presentation Schedule for Triferic Clinical Posters at American Society of Nephrology (ASN) Meeting November 2015


Rockwell Medical, Inc. (NASDAQ:RMTI), a fully-integrated biopharmaceutical company targeting end-stage renal disease (ESRD) and chronic kidney disease (CKD) with innovative products and services for the treatment of iron replacement, secondary hyperparathyroidism and hemodialysis, announced today the presentation schedule for four (4) Triferic clinical abstracts that will be presented at the ASN Kidney Week 2015 Annual Meeting, November 3-8 at the San Diego Convention Center in San Diego, CA. Triferic is the only FDAapproved iron product indicated to replace iron and maintain hemoglobin in hemodialysis patients in the United States.

The following Triferic clinical presentations will be presented at ASN 2015:

Oral Presentation: Friday 11/6/2015; 4:30 PM – 6:30 PM; Session Room 6E

Triferic Maintains Hemoglobin and Iron Balance Long-Term: Phase III Extension Studies
Guss, C., Pratt, RD., Lin, V. and Gupta, A.
Session Title: Balancing Erythropoiesis and Iron Load in CKD

Poster Presentations: Saturday 11/7/2015; 10:00 AM – 12:00 PM

Triferic has a Safety Profile Similar to Placebo: An Integrated Safety Analysis of Phase-2 and Phase-3 Studies
Lin, V., et al.
Session Title: Dialysis: Anemia and Iron Metabolism

Structural Physical and Functional Characteristics of Triferic (Ferric Pyrophosphate Citrate, FPC): A Novel Iron Compound for Pharmaceutical Applications
Gupta, A., et al.
Session Title: Dialysis: Anemia and Iron Metabolism

Triferic Does Not Induce Non-Transferrin Bound Iron or Labile Plasma Iron: In-Vivo/In-Vitro Correlation
Pratt, RD., et al.
Session Title: Drug Pharmacokinetics and Pharmacogenomics in CKD (Original Source)

Shares of Rockwell Medical closed yesterday at $12.21. RMTI has a 1-year high of $18.90 and a 1-year low of $7.09. The stock’s 50-day moving average is $10.03 and its 200-day moving average is $12.13.

On the ratings front, Rockwell has been the subject of a number of recent research reports. In a report issued on October 21, Oppenheimer analyst Ling Wang reiterated a Buy rating on RMTI, with a price target of $26, which implies an upside of 112.9% from current levels. Separately, on August 13, Morgan Stanley’s Andrew Berens initiated coverage with a Sell rating on the stock and has a price target of $7.

According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Ling Wang and Andrew Berens have a total average return of -8.2% and 11.2% respectively. Wang has a success rate of 33.3% and is ranked #3597 out of 3804 analysts, while Berens has a success rate of 55.6% and is ranked #993.

Rockwell Medical Inc is a biopharmaceutical company targeting end-stage renal disease and chronic kidney disease with products and services for the treatment of iron deficiency, secondary hyperparathyroidism and hemodialysis.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts